Arcutis Biotherapeutics Inc

ARQT sits in distribution after a support failure break below key short-term EMAs and horizontal support, with price rejected at declining EMAs and heavy volume confirming selling pressure. Medium-term bias is bearish, offering execution on rallies into resistance zones near the broken support. Short-term weakness and RSI below 50 confirm timing to Sell Now, though extreme oversold conditions pose a mean-reversion risk.

• ↑Q2 product revenue surged 59% YoY to $129.9M, beating estimates
• ↑Net income reached $15M vs. a $15.9M loss a year ago
• ↓Negative earnings yield and low book-to-price raise valuation concerns